Dr. Dmitriy Zamarin

Dr. Dmitriy Zamarin anchors the Section of Gynecologic Medical Oncology at the Tisch Cancer Institute, part of the NCI-designated Icahn School of Medicine at Mount Sinai, where ovarian, cervical, and endometrial experts convene around each patient’s story rather than around siloed specialties. Board-certified in medical oncology and internal medicine, he chairs interdisciplinary tumor boards that juxtapose genomic data, imaging findings, and quality-of-life goals so the first therapeutic decision is also the most nuanced. Nurse navigators, genetic counselors, palliative-care physicians, and rehabilitation therapists collaborate in real time, ensuring that supportive measures rise in parallel with disease-directed therapy—a model that shortens time to treatment while preserving dignity. With consult notes written in plain language and follow-up calls scheduled before discharge, families feel orientation rather than overwhelm. That blend of rigorous science and human-centered coordination defines Dr. Zamarin’s promise: patients receive sophisticated gynecologic cancer care, ovarian cancer specialist expertise, multidisciplinary oncology guidance without ever losing sight of their personal priorities.

 

Beyond the clinic, Dr. Zamarin runs a laboratory focused on harnessing oncolytic viruses and checkpoint blockade to expose gynecologic malignancies to the full force of the immune system. Bench teams dissect how viral vectors reshape the tumor microenvironment, then translate those insights into trials that combine viral therapy with PD-L1 inhibition—a flagship strategy already opening durable options for patients whose cancers resist standard regimens. Continuous data exchange between sequencing cores, animal models, and biorepositories accelerates biomarker discovery, allowing real-time adjustments to trial arms once resistance patterns emerge. Interactions with bioinformaticians refine single-cell RNA maps, while collaborations with immunologists optimize vaccine platforms that expand tumor-specific T-cell repertoires. This oncolytic virus therapy, cancer immunotherapy research, translational oncology agenda collapses the distance between discovery and delivery, placing tomorrow’s mechanisms into today’s infusion suite for women who need answers now.

 

A natural teacher, Dr. Zamarin mentors fellows, lectures at international symposia, and co-authors consensus statements that recalibrate guidelines as evidence evolves. He serves as translational research co-chair on the NRG Oncology Cervical Cancer Committee, helping shape national trial priorities, and consults for regulatory working groups that assess safety signals in immuno-oncology. Community-facing forums—held in neighborhood clinics, streamed in multiple languages—explain clinical-trial eligibility, fertility preservation, and survivorship planning, ensuring information equity. Podcasts and peer-reviewed editorials distill dense immunology into actionable insights for primary-care physicians, strengthening the referral network that catches disease earlier. Through these education programs, patient advocacy initiatives, and community cancer outreach efforts, families meet a physician-scientist whose influence reaches from global policy tables to local support groups, reinforcing trust that their care aligns with the highest collective expertise.